Category: IPF
-
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lun
•
The first scientific presentation of previously announced data from Cohort 1 of an ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg twice daily) in IPF, confirms positive trends in seven of the eight biomarkers evaluated, suggesting to a potential therapeutic effect Enrollment in the second cohort evaluating high-dose…